Westpac Banking Corp Sells 6,592 Shares of Repligen Corporation $RGEN

Westpac Banking Corp cut its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 33.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 13,116 shares of the biotechnology company’s stock after selling 6,592 shares during the quarter. Westpac Banking Corp’s holdings in Repligen were worth $1,753,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Brown Capital Management LLC increased its holdings in Repligen by 16.3% in the 2nd quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after purchasing an additional 141,241 shares in the last quarter. Stephens Investment Management Group LLC grew its holdings in shares of Repligen by 14.4% during the third quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock worth $79,982,000 after purchasing an additional 75,509 shares during the last quarter. Geneva Capital Management LLC increased its stake in shares of Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after buying an additional 343,991 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Repligen by 6.7% in the third quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock valued at $61,331,000 after buying an additional 28,716 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after buying an additional 400,970 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In related news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.20% of the stock is owned by insiders.

Repligen Stock Performance

Shares of RGEN stock opened at $133.65 on Friday. The firm has a 50 day moving average of $154.86 and a 200-day moving average of $146.68. The company has a market cap of $7.52 billion, a price-to-earnings ratio of 157.24, a price-to-earnings-growth ratio of 2.50 and a beta of 1.13. The company has a quick ratio of 7.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same period in the prior year, the firm earned $0.44 earnings per share. Repligen’s revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Barclays decreased their price target on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 17th. Finally, UBS Group lowered their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.58.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.